期刊文献+

吸入丙酸氟替卡松对支气管哮喘患者肾上腺功能影响的meta分析 被引量:1

Inhaled fluticasone propionate and adrenal effects in adult bronchial asthma: a meta-analysis
原文传递
导出
摘要 目的根据现有临床研究评价吸入丙酸氟替卡松(FP)对支气管哮喘(简称哮喘)患者肾上腺功能影响的剂量-效应关系。方法从1978—2007年MEDLINE光盘数据库和1978—2007年中国生物医学光盘数据库,检索哮喘患者吸入FP为研究对象、比较吸入FP4周后,进行促肾上腺皮质素刺激实验的随机对照实验文献,对肾上腺功能影响的剂量-效应关系进行随机、安慰剂对照的meta分析。结果有5项研究中的732例哮喘患者符合纳入标准,安慰剂组肾上腺功能低于正常值例数是3.9%;FP组增加至500μg/d的剂量,肾上腺功能异常增加的比数比是1.38(95%的可信限为1.01~1.59);当FP逐渐增加至2000μg/d,与肾上腺功能异常呈线性关系。结论常规应用FP200-500μg/d是安全的,对肾上腺功能的影响很小。 Objective To pool the data of studies about the dose-response relationship of inhaled flutieasone propionate(FP) for adrenal suppression in adults with bronchial asthma(asthma). Methods The meta-analysis of placebo-controlled randomised dose-response studies of ≥4 weeks' duration were chosen from MEDLINE disks from 1978 to 2007 and CBM disks from 1978 to 2007, which assessed the adrenal effects of FP by cosyntropin stimulation tests in adult asthma. Results Five studies, with a total of 732 subjects with asthma,met the inclusion criteria. The proportion of subjects with adrenal function below the lower limit of the normal range on placebo was 3.9% .for increase up to 500μg per day in FP dose,the odds of an abnormality increased by 1.38 (950/00 confidence interval 1.01-1.59). The outcome measures showed an inverse linear relationship with the FP dose up to 2 000 μg per day. Conclusions For routine prescribing within the established therapeutic dose-response range (200-500 μg per day), FP has minimal effects on adrenal function.
出处 《国际呼吸杂志》 2009年第21期1285-1288,共4页 International Journal of Respiration
关键词 支气管哮喘 丙酸氟替卡松 肾上腺功能 Bronchial ashtma Flutieasone propionate Drenal function
  • 相关文献

参考文献20

  • 1Holt S,Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma:meta-analysis. BMJ ,2001,323:253-256.
  • 2Masoli M,Weatherall M, Holt S, et al. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax, 2004,59 : 16-20.
  • 3NHLBI/WHO Workshop Report: Globl Strategy for Asthma Management and Prevention. NIH Publication No 02-3659, 2002 : 104-106.
  • 4Aron DC. Diagnostic implications of adrenal physiology and clinical epidemiology for evaluation of glucocorticoid excess and deficiency. In: De Groot LJ, Jameson JL, eds. Endocrinology. 4th Edn. Philadelphia, WB Saunders, 2001: 1655-1670.
  • 5Isselbaeher KJ, Braunwald E, Wilson JD, et al. Harrison's Principles of Internal Medicine. 13th Edn. New York, McGraw-Hill Ine, 1994 : 1953-1976.
  • 6Kellerman D, Stricker W, Howland W. Effects of inhaled fluticasone propionate (FP) on the HPA axis of patients with asthma. Eur Respir J, 1996,9 (Suppl 23 ) :162s.
  • 7Sorkness CA, LaForce C, Storms W, et al. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther, 1999,21 : 353-367.
  • 8Li JT,Goldstein MF, Gross GN, et al. Effects of fluticasone propionate, trlamcinolone acetonlcle, prednlsone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol, 1999,103 : 622-629.
  • 9Wasserman SI,Gross GN,Schoenwetter WF,et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma, 1996,33:265-274.
  • 10Tita J, LaForce C, Howland WC, et al. Use of 6-hr cosyntropin stimulation tests to evaluate potential effects of inhaled fluticasone propionate (FP), inhaled triamcinolone acetonide (TAA), placebo (PBO) and oral prednisone on HPA axis function. Am J Respir Crit Care Med, 1997, 155: A355.

同被引文献32

  • 1郭海英,陈钦,朱小敏,金先桥.吸入丙酸氟替卡松干粉剂每日1000微克对支气管哮喘患者肾上腺皮质功能的影响[J].中国医师进修杂志(内科版),2007,30(1):24-25. 被引量:4
  • 2Barnes NC. The properties of inhaled corticosteroids: similarities and differences [J]. Prim Care Respir J, 2007,16 ( 3 ) : 149-154.
  • 3Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma[J]. Curr Opin Allergy Clin Immunol, 2011,11 ( g ) : 337-344.
  • 4Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in Children with asthma [J]. Pediatrics ,2008,121 ( 1 ) : 1-14.
  • 5Zhang L, Axelsson I, Chung M,et al. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review [J]. Pediatrics,2011,127 ( 1 ) : 129-138.
  • 6Molimard M, Le Gros V, Robinson P, et al. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting[J]. J Aerosol Med Pulm Drug Deliv, 2010,23(2) :91-95.
  • 7Roland NJ,Bhalla RK,Earis J. The local side Effects of inhaled corticosteroids current understanding and Review of the literature [J]. Chest,2004,126( 1 ) :213-219.
  • 8Kurt E, Yildirim H, Kiraz N, et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate:500 microg/day versus 200 microg/day [J]. Allergol Immunopathol ( Madr ) , 2008,36 ( 1 ) : 17-20.
  • 9Irwin RS, Richardson ND. Side effects with inhaled corticosteroids the physician's perception[ J]. Chest ,2006,130 ( 1 ) :41-53.
  • 10Newman SP. Spacer devices for metered dose inhalers [ J ]. Clin Pharmacokinet, 2004,43 ( 6 ) : 349-360.

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部